Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden

NCT06769256 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

ST-segment Elevation Myocardial Infarction (STEMI)

Interventions

DRUG: rhTNK-tPA, 4-8 mg
DRUG: Tirofiban

Sponsor

Henan Institute of Cardiovascular Epidemiology